NASDAQ:CDXS Codexis (CDXS) Stock Forecast, Price & News $2.54 -0.02 (-0.78%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$2.49▼$2.6050-Day Range$2.21▼$4.4352-Week Range$2.18▼$13.03Volume398,749 shsAverage Volume768,081 shsMarket Capitalization$169.59 millionP/E RatioN/ADividend YieldN/APrice Target$15.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Codexis MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside510.2% Upside$15.50 Price TargetShort InterestBearish6.03% of Float Sold ShortDividend StrengthN/ASustainability-3.67Upright™ Environmental ScoreNews Sentiment0.52Based on 3 Articles This WeekInsider TradingSelling Shares$293,926 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.91) to ($0.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector501st out of 987 stocksIndustrial Organic Chemicals Industry10th out of 20 stocks 3.3 Analyst's Opinion Consensus RatingCodexis has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.50, Codexis has a forecasted upside of 510.2% from its current price of $2.54.Amount of Analyst CoverageCodexis has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.03% of the float of Codexis has been sold short.Short Interest Ratio / Days to CoverCodexis has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Codexis has recently decreased by 1.52%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCodexis does not currently pay a dividend.Dividend GrowthCodexis does not have a long track record of dividend growth. Previous Next 2.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCodexis has received a 14.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Industrial enzymes for pharmaceuticals", "Biochemical assay kits", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Codexis is -3.67. Previous Next 2.0 News and Social Media Coverage News SentimentCodexis has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Codexis this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CDXS on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Codexis to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Codexis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $293,926.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Codexis is held by insiders.Percentage Held by Institutions93.41% of the stock of Codexis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Codexis are expected to grow in the coming year, from ($0.91) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Codexis is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Codexis is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCodexis has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Codexis (NASDAQ:CDXS) StockCodexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.Read More Receive CDXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter. Email Address CDXS Stock News HeadlinesJune 8, 2023 | finance.yahoo.comThe Market Doesn't Like What It Sees From Codexis, Inc.'s (NASDAQ:CDXS) Revenues YetMay 24, 2023 | finance.yahoo.comCodexis to Participate in Jefferies Healthcare ConferenceJune 10, 2023 | Vantage Point (Ad)Trade Smarter: Discover Hidden Opportunities w/ A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 19, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Lifted to "Hold" at StockNews.comMay 11, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Cut to Neutral at HC WainwrightMay 11, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Price Target Cut to $9.00May 11, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Downgraded to "Sell" at StockNews.comMay 10, 2023 | finance.yahoo.comCodexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USAJune 10, 2023 | Vantage Point (Ad)Trade Smarter: Discover Hidden Opportunities w/ A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 10, 2023 | americanbankingnews.comCodexis, Inc. to Post Q1 2024 Earnings of ($0.27) Per Share, HC Wainwright Forecasts (NASDAQ:CDXS)May 9, 2023 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Codexis (CDXS)May 9, 2023 | americanbankingnews.comCodexis (NASDAQ:CDXS) Downgraded to "Neutral" at HC WainwrightMay 5, 2023 | finance.yahoo.comCodexis (CDXS) Reports Q1 Loss, Lags Revenue EstimatesMay 4, 2023 | finance.yahoo.comCodexis Reports First Quarter 2023 Financial ResultsApril 28, 2023 | finance.yahoo.comWhat Is Codexis, Inc.'s (NASDAQ:CDXS) Share Price Doing?April 27, 2023 | americanbankingnews.comCodexis (CDXS) to Release Earnings on ThursdayApril 20, 2023 | americanbankingnews.comCodexis, Inc. (NASDAQ:CDXS) Director John J. Nicols Sells 35,714 SharesApril 19, 2023 | finance.yahoo.comCodexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USAApril 19, 2023 | americanbankingnews.comPiper Sandler Trims Codexis (NASDAQ:CDXS) Target Price to $14.00April 18, 2023 | msn.comPiper Sandler Maintains Codexis (CDXS) Overweight RecommendationApril 4, 2023 | finance.yahoo.comCodexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of DirectorsMarch 27, 2023 | finance.yahoo.comCodexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 24% Below Its Share PriceFebruary 27, 2023 | finance.yahoo.comCodexis to Participate in Cowen 43rd Annual Health Care ConferenceFebruary 27, 2023 | finance.yahoo.comThese Analysts Think Codexis, Inc.'s (NASDAQ:CDXS) Sales Are Under ThreatFebruary 24, 2023 | finance.yahoo.comQ4 2022 Codexis Inc Earnings CallFebruary 15, 2023 | finance.yahoo.comCodexis Announces New Employment Inducement GrantsFebruary 9, 2023 | finance.yahoo.comCodexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23See More Headlines CDXS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDXS Company Calendar Last Earnings5/04/2023Today6/10/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Industrial organic chemicals Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CDXS CUSIP19200510 CIK1200375 Webwww.codexis.com Phone(650) 421-8100Fax650-421-8102Employees261Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.50 High Stock Price Forecast$21.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+510.2%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,590,000.00 Net Margins-41.17% Pretax Margin-40.93% Return on Equity-32.75% Return on Assets-20.39% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.34 Sales & Book Value Annual Sales$116.23 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / Book1.15Miscellaneous Outstanding Shares66,768,000Free Float62,094,000Market Cap$169.59 million OptionableOptionable Beta1.64 Key ExecutivesStephen George DillyPresident, CEO & Independent DirectorKarl A. SchoeneSenior Vice President-Development & OperationsKevin NorrettChief Operating OfficerSriram RyaliChief Financial & Accounting OfficerStefan LutzSenior Vice President-ResearchKey CompetitorsSHL TelemedicineNASDAQ:SHLTBioAtlaNASDAQ:BCABMerrimack PharmaceuticalsNASDAQ:MACKJasper TherapeuticsNASDAQ:JSPRHealth Sciences Acquisitions Co. 2NASDAQ:HSAQView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Sold 27,429 shares on 5/22/2023Ownership: 1.181%Putnam Investments LLCSold 6,523 shares on 5/22/2023Ownership: 0.231%JPMorgan Chase & Co.Bought 42,663 shares on 5/18/2023Ownership: 0.208%New York State Common Retirement FundSold 21,806 shares on 5/18/2023Ownership: 0.025%Thrivent Financial for LutheransBought 55,516 shares on 5/17/2023Ownership: 0.083%View All Insider TransactionsView All Institutional Transactions CDXS Stock - Frequently Asked Questions Should I buy or sell Codexis stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CDXS shares. View CDXS analyst ratings or view top-rated stocks. What is Codexis' stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month target prices for Codexis' stock. Their CDXS share price forecasts range from $9.00 to $21.00. On average, they expect the company's share price to reach $15.50 in the next year. This suggests a possible upside of 510.2% from the stock's current price. View analysts price targets for CDXS or view top-rated stocks among Wall Street analysts. How have CDXS shares performed in 2023? Codexis' stock was trading at $4.66 at the beginning of the year. Since then, CDXS shares have decreased by 45.5% and is now trading at $2.54. View the best growth stocks for 2023 here. When is Codexis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CDXS earnings forecast. How were Codexis' earnings last quarter? Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, May, 4th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.05. The biotechnology company had revenue of $12.98 million for the quarter, compared to analyst estimates of $14.09 million. Codexis had a negative net margin of 41.17% and a negative trailing twelve-month return on equity of 32.75%. The firm's revenue was down 63.3% compared to the same quarter last year. During the same period last year, the business posted ($0.13) EPS. What ETFs hold Codexis' stock? ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS) and WisdomTree BioRevolution Fund (WDNA).Inspire Small/Mid Cap ETF (ISMD) and What guidance has Codexis issued on next quarter's earnings? Codexis updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $63.00 million-$68.00 million, compared to the consensus revenue estimate of $74.57 million. What is John J. Nicols' approval rating as Codexis' CEO? 25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees. What other stocks do shareholders of Codexis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS). What is Codexis' stock symbol? Codexis trades on the NASDAQ under the ticker symbol "CDXS." Who are Codexis' major shareholders? Codexis' stock is owned by a variety of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.26%), BlackRock Inc. (9.06%), ARK Investment Management LLC (6.51%), Telemark Asset Management LLC (3.84%), State Street Corp (2.58%) and FMR LLC (2.45%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Patrick Y Yang and Stephen George Dilly. View institutional ownership trends. How do I buy shares of Codexis? Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Codexis' stock price today? One share of CDXS stock can currently be purchased for approximately $2.54. How much money does Codexis make? Codexis (NASDAQ:CDXS) has a market capitalization of $169.59 million and generates $116.23 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. How many employees does Codexis have? The company employs 261 workers across the globe. How can I contact Codexis? Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102. This page (NASDAQ:CDXS) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Codexis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.